References
- Ballard TE, Orozco CC, Obach RS. (2014). Generation of major human excretory and circulating drug metabolites using a hepatocyte relay method. Drug Metab Dispos 42:899–902.
- Bloomer J, Beaumont C, Dear GJ, et al. (2016). Case studies: GlaxoSmithKline. In: S. L. Iverson and Dennis A. Smith, ed. Metabolite Safety in Drug Development. Hoboken, NJ: John Wiley & Sons Inc., 275–91.
- Di L, Trapa P, Obach RS, et al. (2012). A novel relay method for determining low-clearance values. Drug Metab Dispos 40:1860–5.
- Di L, Atkinson K, Orozco CC, et al. (2013). In vitro-in vivo correlation for low-clearance compounds using hepatocyte relay method. Drug Metab Dispos 41:2018–23.
- Erion DM, Lapworth A, Amor PA, et al. (2014). The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One 9:e97139.
- Food and Drug Administration (FDA), 2008. Guidance for Industry: Safety Testing of Drug Metabolites. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD.
- FDA (2016) Guidance for Industry: Safety Testing of Drug Metabolites. Silver Spring, MD: US Department of Health and Human Services FaDA, Center for Drug Evaluation and Research.
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13.
- Hastings KL, El-Hage J, Jacobs A, et al. (2003). Drug metabolites in safety testing. Toxicol Appl Pharmacol 190:91–2.
- International Conference on Harmonization (ICH) (2010) M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals.
- International Conference on Harmonization (ICH) (2013) M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Questions and Answers(R2).
- Kazierad DJ, Bergman AJ, Pfefferkorn JA, et al. (2013a). Pharmacokinetics and pharmacodynamics of PF-04991532, a hepatoselective glucokinase activator (GKA), administered as monotherapy in Japanese and non-Japanese T2DM patients. American Diabetes Association. 73rd Scientific Sessions, June 21-25, 2013, Chicago IL, 1050-P.
- Kazierad DJ, Pfefferkorn JA, Bergman A, et al. (2013b). The hepatoselective glucokinase activator, PF-04991532, lowers HbA1c after 12 weeks of dosing in patients with type 2 diabetes. American Diabetes Association. 73rd Scientific Sessions, June 21-25, 2013, Chicago IL, 1051-P.
- Li Y, Zhou J, Ramsden D, et al. (2014). Enzyme-transporter interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta but not in circulation. Drug Metab Dispos 42:384–93.
- Liu H, Michmerhuizen MJ, Lao Y, et al. (2017). Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites. Drug Metab Dispos 45:294–305.
- Luffer-Atlas D, Atrakchi A. (2017). A decade of drug metabolite safety testing: industry and regulatory shared learning. Expert Opin Drug Metab Toxicol 13:897–900.
- Pfefferkorn JA, Guzman-Perez A, Litchfield J, et al. (2012). Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nictonic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 55:1318–33.
- Ramsden DI, Tweedie DJ, Chan TS, et al. (2014). Bridging the in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac. Drug Metab Dispos 42:394–406.
- Sarabu R, Bizzarro FT, Corbett WL, et al. (2012). Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients. J Med Chem 55:7021–36.
- Schadt S, Bister B, Chowdhury SK, et al. (2018). A decade in the MIST: Learnings from investigations of drug metabolites in drug development under the “Metabolites in Safety Testing” Regulatory Guidance”. Drug Metab Dispos 46:865–78.
- Sharma R, Litchfield J, Atkinson K, et al. (2014). Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator. Drug Metab Dispos 42:1926–39.
- Sharma R, Litchfield J, Bergman A, et al. (2015). Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment. Drug Metab Dispos 43:190–8.